AlphaStocks

AMRX vs AZN

Amneal Pharmaceuticals, Inc. vs ASTRAZENECA PLC — Side-by-Side Stock Comparison

AMRX

Amneal Pharmaceuticals, Inc.

6.4

Consider Buy

$12.70

AZN

ASTRAZENECA PLC

8.4

Strong Buy

$200.99

AMRX vs AZN: Which is the Better Investment?

Amneal Pharmaceuticals, Inc. (AMRX) scores 6.4/10 while ASTRAZENECA PLC (AZN) scores 8.4/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, ASTRAZENECA PLC trades at 30.4x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricAMRXAZN
Scores & Fundamentals
Composite Score6.4/108.4/10
RatingConsider BuyStrong Buy
Price$12.70$200.99
P/E Ratio57.330.4
ROE-80.0%21.9%
Market Cap$4B$312B
Fair Value$8.39$192.63
Dividend Yield1.6%
Sector Rank#195 of 1127#3 of 1127
Model Verdicts
PiotroskiStrongStrong
BuffettNeutralStrong
GrahamNeutralCaution
LynchAttractiveNeutral
GreenblattAttractiveNeutral
View full AMRXanalysis →View full AZNanalysis →
Compare any two stocks →

AMRX vs AZN: Which Stock Scores Higher?

Amneal Pharmaceuticals, Inc. (AMRX) and ASTRAZENECA PLC (AZN) are among the most compared stocks in the Health Care sector. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to AMRX's 6.4/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer